# Junta clínica — PT-pseudo_6d2ecb82cc52 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_6d2ecb82cc52",
  "pid": "PT-pseudo_6d2ecb82cc52",
  "task": 1,
  "psa": 25.0,
  "age": 60,
  "months": 1,
  "pirads": "5",
  "psad": 0.783,
  "psav": 12.01,
  "psap": 13.2,
  "vol": 31.91,
  "dre": "Abnormal",
  "bx": "Positive",
  "cspca": 0.918368,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 25 ng/mL. PI-RADS 5. PSAD 0.78. Prostate volume 32 mL. DRE abnormal. csPCa 0.92.",
  "pmhx": [],
  "allergies": [
    "Iodinated contrast (mild)"
  ],
  "vitals": {
    "weight": "71 kg",
    "height": "182 cm",
    "bmi": "21.4",
    "bp": "130/75 mmHg",
    "hr": "64 bpm",
    "smoking": "Ex-smoker (40 pack-yr, quit 2005)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "02 Jan 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent elevation of prostate-specific antigen coupled with an abnormal digital rectal examination."
    },
    {
      "s": "History",
      "t": "A 60-year-old married man residing with his partner, this active dairy farmer initially sought evaluation after an elevated PSA reading surfaced in early 2022. He is an ex-smoker (40 pack-yr, quit 2005). He experiences moderate lower urinary tract symptoms, scoring 10 out of 35 on the IPSS questionnaire, though he requires no pharmacological intervention. Weekly alcohol consumption sits at roughly 10 units, complemented by a weekly swimming routine. He reports no chronic illnesses and takes no daily medications."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals an asymmetrically enlarged gland featuring a firm, irregular nodule within the left peripheral zone. The right lobe exhibits slightly reduced compliance without discrete focal induration. General inspection remains unremarkable."
    }
  ],
  "occupation": "active dairy farmer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Pulmonary function test — known COPD follow-up"
  ],
  "alcohol": "10 units / week",
  "exercise": "Swimming 1x/week",
  "ipss": "IPSS score: 10/35 (moderate LUTS)",
  "admin": "Mobility limitation (frame); ground-floor consult room preferred.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_6d2ecb82cc52
Task: 1

Encounter: Urology - outpatient on 02 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 25.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.783 ng/mL²
  - PSA velocity: 12.01 ng/mL/yr
  - Prior PSA: 13.2 ng/mL
  - Prostate volume: 31.91 mL
  - Months since last PSA: 1
  - DRE findings: Abnormal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.918368 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: Iodinated contrast (mild)
  - Additional notes: PSA 25 ng/mL. PI-RADS 5. PSAD 0.78. Prostate volume 32 mL. DRE abnormal. csPCa 0.92.

Vitals: weight 71 kg, height 182 cm, BMI 21.4, BP 130/75 mmHg, HR 64 bpm. Smoking: Ex-smoker (40 pack-yr, quit 2005).

Chief complaint: Persistent elevation of prostate-specific antigen coupled with an abnormal digital rectal examination.

History: A 60-year-old married man residing with his partner, this active dairy farmer initially sought evaluation after an elevated PSA reading surfaced in early 2022. He is an ex-smoker (40 pack-yr, quit 2005). He experiences moderate lower urinary tract symptoms, scoring 10 out of 35 on the IPSS questionnaire, though he requires no pharmacological intervention. Weekly alcohol consumption sits at roughly 10 units, complemented by a weekly swimming routine. He reports no chronic illnesses and takes no daily medications.

Physical examination: DRE reveals an asymmetrically enlarged gland featuring a firm, irregular nodule within the left peripheral zone. The right lobe exhibits slightly reduced compliance without discrete focal induration. General inspection remains unremarkable.

Patient info: active dairy farmer; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 10 units / week; exercise Swimming 1x/week; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up.
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.11 epistemic (95% band 0.26-0.68); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = none recorded (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 60 (2% of my signal; from age) · DRE = Abnormal (10% of my signal; from dre_suspicious) · PSA = 25 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 31.91 mL (1% of my signal; from log_vol, vol) · PSA density = 0.783 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.92 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PSA = 25 ng/mL
  important  prior biopsy = Positive
  noted      age = 60 · DRE = Abnormal · prostate volume = 31.91 mL · PSA density = 0.783 · PI-RADS = 5 · comorbidity = none recorded
  not used   family history, csPCa probability
CONFIDENCE: uncertain — the rule matched the reading urologist in only 5 of 6 labelled cases

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.10: PI-RADS 5, PSA 28.3, PSAD 0.4, age 61, DRE Nodus -> DEFER (clear). He wrote: "Highrisk disease in young patient. Should be treated, not get another biopsy."
  2. distance 1.54: PI-RADS 5, PSA 10.92, PSAD 0.26, age 61, DRE Nodus -> DEFER (clear). He wrote: "Advocate for curative treatment while unfavorable intermediate risk pc in young patient without significant comorbidity. IF he is cautious toward curative treatment, rep…"
  3. distance 1.98: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"

PRECEDENT: DEFER (weighted vote 0.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   prior biopsy = Positive
  important  age = 60 · DRE = Abnormal · PSA = 25 ng/mL · PSA density = 0.783 · PI-RADS = 5
  noted      family history = not opened (0 of 91) · prostate volume = 31.91 mL · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   prior biopsy = Positive · PI-RADS = 5
  important  age = 60 · DRE = Abnormal · PSA = 25 ng/mL
  noted      family history = not opened (0 of 91) · prostate volume = 31.91 mL · PSA density = 0.783 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using a risk-adapted matrix based on PI-RADS score and PSA density to guide the decision to perform a biopsy. It states, "This risk-adapted matrix table may guide the decision to perform a biopsy." It also notes that in a risk-based pathway, biopsy could have been avoided in 99 men while missing ISUP GG 2 cancers in only six men.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your variable 'prior biopsy = Positive' is decisive, whereas the guideline treats it as context. The guideline suggests that the decision should be guided by the PI-RADS score and PSA density, which are variables that EXPERT-STRUCTURED marked as 'noted'. The guideline suggests that for this patient, the decision should be guided by the PI-RADS score and PSA density, which are variables that EXPERT-STRUCTURED marked as 'noted'. The guideline requires a comparison MRI to be established to determine the next step.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at Positive the guideline suggests that the decision should be guided by the PI-RADS score and PSA density.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the guideline suggests that the decision should be guided by the PI-RADS score and PSA density.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 5 and PSA density are sufficient to override the prior positive biopsy status, as suggested by the EAU guideline.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size and zone, extraprostatic extension, and comparison against an earlier study inform the decision?
  psa_trend (get_psa_trend) -> Does the PSA trend inform the decision based on the PI-RADS score and PSA density?
  previous_notes (get_previous_notes) -> Is the grade of the prior biopsy recorded (Gleason or ISUP)? How many biopsy sessions, and when was the last? Is he on a surveillance protocol, and is a confirmatory biopsy due? Is any treatment already agreed or declined?
  laboratory_results (get_lab_results) -> Free-PSA fraction, and anything that would explain the PSA (infection, prostatitis) or bear on fitness for the procedure (renal function, coagulation).

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the comparison MRI status as described in the radiology_report?
  Q2. What is the PSA trend as described in the psa_trend?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report: "Radiology Division | Antoni van Leeuwenhoek | 02 Jan 2025 | Multiparametric MRI Prostate\n\nClinical Indication: Rising PSA (25.0 ng/mL) paired with an abnormal digital rectal examination; prior biopsy bucket Positive.\n\nFINDINGS:\nProstate volume registers at 31.91 mL. A discrete focus occupies the left peripheral zone spanning the base to mid-gland, spanning roughly 18 mm. T2 sequences show pronounced hypointensity with poorly demarcated borders. Diffusion-weighted imaging highlights restricted movement alongside low ADC mapping, pointing toward high cellular density. Post-contrast dynamics capture early, localized enhancement against the background parenchyma. No extraprostatic spread or seminal vesicle infiltration is seen.\n\nIMPRESSION:\nPI-RADS 5 lesion in the left peripheral zone (base/mid), measuring approximately 18 mm. Prostate volume 31.91 mL. PSA density 0.783 ng/mL/mL. csPCa predicted probability 0.918368."
psa_trend: "PSA 2.1 (Mar 2022) rising to 25.0 (Jan 2025), steepest in the last year"
previous_notes: "PRIOR GRADE: not recorded\nBIOPSY SESSIONS: not recorded\nSURVEILLANCE: not recorded\nTREATMENT: none recorded"
laboratory_results: "Free-PSA fraction: 5.68 ng/mL, %Free PSA: 23% on 30 Nov 2024. Renal function (Creatinine: 80 umol/L, eGFR: >60 mL/min/1.73m2) is normal."

WHAT I DID NOT OPEN
family-history anamnesis, because it is not relevant to the immediate decision based on the opened documents.

WHAT THIS SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion in the left peripheral zone (base/mid), measuring approximately 18 mm, with high cellular density.
- psa_trend: PSA 2.1 (Mar 2022) rising to 25.0 (Jan 2025), steepest in the last year, indicating significant progression.

AGAINST sampling this patient now:
- previous_notes: BIOPSY SESSIONS: not recorded, suggesting no immediate need for repeat tissue sampling based on history.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 25.00 ng/mL over 3 points spanning 34 months; velocity +7.91 ng/mL per year; doubling time about 10 months.
PROJECTION at 6 months: 27.1 ng/mL, conformal 95% band 7.8-94.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 25 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: uncertain — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.59
  uncertainty  +/- 0.10 epistemic (95% band 0.39-0.78), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Abnormal (5% of my signal; from dre_suspicious) · PSA = 25 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 31.91 mL (4% of my signal; from log_vol, vol) · PSA density = 0.783 (0% of my signal; from psad_calc) · comorbidity = none recorded (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.47  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.59  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule psa_ge_20; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).
Dissenting on the board: EXPERT-FUSION. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:DEC E2:—            -> decisive
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          60                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Abnormal                     E1:not E3:not cohort:not library:IMP E2:—            -> important
  psa          25 ng/mL                     E1:not E3:not cohort:DEC library:IMP E2:not          -> important
  vol          31.91 mL                     E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.783                        E1:not E3:not cohort:not library:IMP E2:—            -> noted
  cspca        0.92                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:IMP E2:—            -> decisive
  comorbidity  none recorded                E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened appear to answer the moderator's questions. The `radiology_report` describes the lesion and comparison status, and the `psa_trend` describes the PSA trend.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of NO BIOPSY. The `psa_trend` shows a significant rise, which aligns with the cohort criterion that fired the panel decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the comparison MRI status as described in the radiology_report? The report states: "No extraprostatic spread or seminal vesicle infiltration is seen," which addresses the comparison aspect by confirming the absence of local extension.
Q2. What is the PSA trend as described in the psa_trend? The trend is described as "PSA 2.1 (Mar 2022) rising to 25.0 (Jan 2025), steepest in the last year," which is a significant finding.

WHAT CARRIES WEIGHT, AND WHY
psa: important: 25 ng/mL, because this value was decisive for the cohort criterion which led to the panel decision.
pirads: decisive: 5, because this score was decisive for the cohort criterion which led to the panel decision.
psa_trend: important: rising to 25.0 (Jan 2025), because this trend was the specific finding that triggered the cohort criterion.
I would not move the levels on the PANEL-PROTOCOL as the evidence retrieved directly supports the rule that fired. My confidence in the record as it stands is clear.

MY SUGGESTION TO THE CHAIR
The record is in a state to be decided based on the panel protocol. The panel-protocol's answer of NO BIOPSY rests on the cohort criterion (PSA >= 20 ng/mL) being met, which is supported by the retrieved PSA value and trend.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

60y male, PSA 25.0, PI-RADS 5, prior positive biopsy. High PSA and known cancer status dictate staging and treatment over repeat biopsy. The PI-RADS 5 finding is expected given prior diagnosis, and no prior biopsy grade is recorded. Plan is staging and treatment.

What carried weight: bx=decisive, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
